Squarepoint Ops LLC lifted its stake in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX – Free Report) by 624.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 589,245 shares of the company’s stock after purchasing an additional 507,960 shares during the period. Squarepoint Ops LLC’s holdings in Avalo Therapeutics were worth $10,889,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in AVTX. Boothbay Fund Management LLC bought a new position in shares of Avalo Therapeutics in the second quarter valued at $56,000. Dimensional Fund Advisors LP bought a new stake in Avalo Therapeutics during the third quarter worth $143,000. AlphaCentric Advisors LLC bought a new stake in Avalo Therapeutics during the first quarter worth $174,000. California State Teachers Retirement System bought a new stake in Avalo Therapeutics during the second quarter worth $196,000. Finally, Jump Financial LLC acquired a new stake in Avalo Therapeutics in the fourth quarter valued at $238,000. Institutional investors and hedge funds own 87.06% of the company’s stock.
Avalo Therapeutics Price Performance
AVTX stock opened at $18.21 on Thursday. The company has a fifty day moving average price of $19.16 and a two-hundred day moving average price of $17.04. Avalo Therapeutics, Inc. has a one year low of $9.54 and a one year high of $24.27. The stock has a market cap of $976.60 million, a price-to-earnings ratio of -4.17 and a beta of 0.78.
Analysts Set New Price Targets
AVTX has been the subject of a number of analyst reports. HC Wainwright decreased their price objective on shares of Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Avalo Therapeutics in a report on Friday, July 24th. Citizens Jmp cut their target price on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a research note on Thursday, May 14th. Guggenheim set a $48.00 price target on Avalo Therapeutics and gave the stock a “buy” rating in a report on Friday, August 7th. Finally, Mizuho boosted their price target on Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $45.10.
Check Out Our Latest Research Report on Avalo Therapeutics
Insider Activity at Avalo Therapeutics
In related news, insider Mittie Doyle sold 1,450 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total value of $26,100.00. Following the transaction, the insider owned 51,776 shares in the company, valued at approximately $931,968. This represents a 2.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 3,129 shares of company stock worth $59,680. Insiders own 4.46% of the company’s stock.
About Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.
Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.
Read More
- Five stocks we like better than Avalo Therapeutics
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Want to see what other hedge funds are holding AVTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avalo Therapeutics, Inc. (NASDAQ:AVTX – Free Report).
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
